# Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)

> **NCT04416100** · — · UNKNOWN · sponsor: **Medical University Innsbruck** · enrollment: 130 (estimated)

## Conditions studied

- Covid-19
- Pulmonary Fibrosis

## Interventions

- **DIAGNOSTIC_TEST:** Pulmonary function tests
- **DIAGNOSTIC_TEST:** Imaging
- **BIOLOGICAL:** Blood sampling

## Key facts

- **NCT ID:** NCT04416100
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-29
- **Primary completion:** 2022-04-28
- **Final completion:** 2022-04-28
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416100, "Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04416100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*